{'fraction_non_alphanumeric': 0.018446601941747572, 'fraction_numerical': 0.000970873786407767, 'mean_word_length': 5.694805194805195, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Opioid Antagonist Naltrexone for the Treatment of Pathological Gambling in Parkinson Disease

AbstractPathological gambling (PG) is a potential complication related to the treatment of Parkinson disease (PD) with dopamine agonists (DA). The cause of this disorder is unknown, but altered dopamine neurotransmission may be involved. ObjectiveWe evaluated the efficacy and tolerability of the opioid antagonist naltrexone in the treatment of PG in PD. MethodsOur cases included 3 patients with PD who developed PG after DA treatment. ResultsPathological gambling did not improve after reduction or discontinuation of DA. These patients responded poorly to serotonin reuptake inhibitors, whereas treatment with opioid antagonist naltrexone resulted in the remission of PG. Naltrexone treatment was well tolerated. In one patient, higher dose of naltrexone resulted in hepatic abnormalities, which resolved after dosage reduction. ConclusionsThe opioid antagonist naltrexone could be an effective option for the treatment of PG in PD.